1992
Double-Blind, Crossover Trial of Fluoxetine and Placebo in Children and Adolescents with Obsessive-Compulsive Disorder
RIDDLE M, SCAHILL L, KING R, HARDIN M, ANDERSON G, ORT S, SMITH J, LECKMAN J, COHEN D. Double-Blind, Crossover Trial of Fluoxetine and Placebo in Children and Adolescents with Obsessive-Compulsive Disorder. Journal Of The American Academy Of Child & Adolescent Psychiatry 1992, 31: 1062-1069. PMID: 1429406, DOI: 10.1097/00004583-199211000-00011.Peer-Reviewed Original ResearchConceptsChildren's Yale-Brown Obsessive Compulsive ScaleObsessive-compulsive disorderYale-Brown Obsessive Compulsive ScaleEffective short-term treatmentSafety of fluoxetineFixed-dose trialCommon drug side effectsCY-BOCS total scoreMajor depressive disorderShort-term treatmentDrug side effectsMagnitude of improvementObsessive Compulsive ScaleFluoxetine groupPlacebo groupFluoxetine treatmentCrossover trialClinical trialsDepressive disorderObsessive-compulsive symptom severitySide effectsFluoxetineSymptom severityTotal scoreCompulsive ScalePlatelet dense granule release reaction monitored by high-performance liquid chromatography-fluorometric determination of endogenous serotonin
Anderson G, Hall L, Yang J, Cohen D. Platelet dense granule release reaction monitored by high-performance liquid chromatography-fluorometric determination of endogenous serotonin. Analytical Biochemistry 1992, 206: 64-67. PMID: 1456443, DOI: 10.1016/s0003-2697(05)80011-9.Peer-Reviewed Original Research
1991
Emergence of Self-Destructive Phenomena in Children and Adolescents during Fluoxetine Treatment
KING R, RIDDLE M, CHAPPELL P, HARDIN M, ANDERSON G, LOMBROSO P, SCAHILL L. Emergence of Self-Destructive Phenomena in Children and Adolescents during Fluoxetine Treatment. Journal Of The American Academy Of Child & Adolescent Psychiatry 1991, 30: 179-186. PMID: 2016219, DOI: 10.1097/00004583-199103000-00003.Peer-Reviewed Original ResearchConceptsFluoxetine treatmentObsessive-compulsive disorderUniversity Clinical Research CenterClinical Research CenterMajor risk factorDrug-induced activationPrior suicidal ideationYounger patientsRisk factorsRegulation of aggressionPatientsSuicidal ideationSelf-destructive behaviorFluoxetineAge 10Apparent associationVulnerable individualsDisordersTreatmentIdeationDe novoHospitalizationSymptoms